Previously SBIR involved as Synspira Therapeutics Inc. - renamed in April 2023 as Anagram Therapeutics Inc. - the firm is a clinical-stage biopharmaceutical company structured around work in arenas of cystic fibrosis (CF) and other rare diseases. Focusing its core enzyme expertise, firm is indicated as accelerating development of ANG003 (formerly SNSP003). Anchored on success with ANG003, company intent is to advance a pipeline of orally delivered enzymes targeting malabsorption syndromes and nutrient metabolism disorders. The company also announced having spun out its pulmonary program, including SNSP113, into a new entity not affiliated with Anagram. Management further announced Cystic Fibrosis Foundation had agreed to provide additional funding to support clinical development of ANG003, Anagrams orally delivered enzyme replacement therapy entering clinical trials in people with CF for the treatment of malabsorption and exocrine pancreatic insufficiency. Anagram's progress is noted to mark a milestone in a twenty-plus-year effort to advance the potential of orally delivered enzymes and supports the development of highly targeted therapeutics to solve complex problems in the gastrointestinal tract. Malabsorption syndromes and nutrient metabolism disorders are conditions caused by enzyme deficiencies or genetic disorders that prevent body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. Anagram is indicated as tackling creation of a new class of orally delivered enzyme replacement therapy (ERT). The companys lead product, ANG003, delivers a broad-spectrum ERT (i.e., lipase for fat, protease for protein, and amylase for carbohydrate), targeting some of the most challenging diseases in infants, children and adults.
